Jeffrey F Scherrer1, Joanne Salas2, James S Floyd3, Susan A Farr4, John E Morley5, Sascha Dublin6. 1. Department of Family and Community Medicine, Saint Louis University School of Medicine, MO; Harry S. Truman Veterans Administration Medical Center, Research Service, Columbia, MO. Electronic address: jeffrey.scherrer@health.slu.edu. 2. Department of Family and Community Medicine, Saint Louis University School of Medicine, MO; Harry S. Truman Veterans Administration Medical Center, Research Service, Columbia, MO. 3. Department of Epidemiology, University of Washington, Seattle; Department of Medicine, University of Washington, Seattle; Cardiovascular Health Research Unit, University of Washington, Seattle. 4. Division of Geriatric Medicine, Saint Louis University School of Medicine, MO; Saint Louis Veterans Affairs Medical Center, Research Service, John Cochran Division, MO. 5. Division of Geriatric Medicine, Saint Louis University School of Medicine, MO. 6. Department of Epidemiology, University of Washington, Seattle; Kaiser Permanente Washington Health Research Institute, Seattle.
Abstract
OBJECTIVE: To compare incident dementia risk among patients who initiated treatment with metformin or sulfonylurea in Veterans Health Affairs (VHA) patients with replication in Kaiser Permanente Washington (KPW) patients to determine whether first-choice antidiabetic medications are associated with reduced risk of dementia. PATIENTS AND METHODS: Cohorts contained 75,187 VHA patients and 10,866 KPW patients, 50 years and older, who initiated monotherapy with metformin or sulfonylurea. Patients were free of dementia diagnoses and any diabetes treatment for 2 years before cohort entry. Variables were extracted from electronic health data from VHA (1999-2015) and KPW (1996-2015), which included diagnosis codes, pharmacy data, laboratory values, and demographic characteristics. Propensity scores and inverse probability of treatment weighting controlled for confounding. RESULTS: Veterans Health Affairs patients were 60.8±6.8 years of age on average, and KPW patients were 63.1±9.5 years of age. In the VHA sample, 72,769 (96.8%) were male; and in the KPW sample, 5480 (50.4%). After adjusting for confounding, metformin initiation was associated with a significantly (P=.02) lower risk of dementia in VHA (hazard ratio, 0.9; 95% CI, 0.9-1.0), with a similar point estimate in KPW (hazard ratio, 0.9; 95% CI, 0.7-1.1). Metformin was not associated with dementia risk in patients 75 years and older. CONCLUSION: Existing epidemiological studies of metformin and incident dementia have been inconsistent. Using a similar study design in 2 patient populations that differed in clinical and demographic characteristics, our results provide robust evidence that metformin use is associated with a modestly lower risk of incident dementia.
OBJECTIVE: To compare incident dementia risk among patients who initiated treatment with metformin or sulfonylurea in Veterans Health Affairs (VHA) patients with replication in Kaiser Permanente Washington (KPW) patients to determine whether first-choice antidiabetic medications are associated with reduced risk of dementia. PATIENTS AND METHODS: Cohorts contained 75,187 VHA patients and 10,866 KPW patients, 50 years and older, who initiated monotherapy with metformin or sulfonylurea. Patients were free of dementia diagnoses and any diabetes treatment for 2 years before cohort entry. Variables were extracted from electronic health data from VHA (1999-2015) and KPW (1996-2015), which included diagnosis codes, pharmacy data, laboratory values, and demographic characteristics. Propensity scores and inverse probability of treatment weighting controlled for confounding. RESULTS: Veterans Health Affairs patients were 60.8±6.8 years of age on average, and KPW patients were 63.1±9.5 years of age. In the VHA sample, 72,769 (96.8%) were male; and in the KPW sample, 5480 (50.4%). After adjusting for confounding, metformin initiation was associated with a significantly (P=.02) lower risk of dementia in VHA (hazard ratio, 0.9; 95% CI, 0.9-1.0), with a similar point estimate in KPW (hazard ratio, 0.9; 95% CI, 0.7-1.1). Metformin was not associated with dementia risk in patients 75 years and older. CONCLUSION: Existing epidemiological studies of metformin and incident dementia have been inconsistent. Using a similar study design in 2 patient populations that differed in clinical and demographic characteristics, our results provide robust evidence that metformin use is associated with a modestly lower risk of incident dementia.
Authors: Stanley Xu; Colleen Ross; Marsha A Raebel; Susan Shetterly; Christopher Blanchette; David Smith Journal: Value Health Date: 2009-11-12 Impact factor: 5.725
Authors: Insa Feinkohl; Phyu Phyu Aung; Marketa Keller; Christine M Robertson; Joanne R Morling; Stela McLachlan; Ian J Deary; Brian M Frier; Mark W J Strachan; Jackie F Price Journal: Diabetes Care Date: 2013-10-08 Impact factor: 19.112
Authors: Jeffrey F Scherrer; John E Morley; Joanne Salas; James S Floyd; Susan A Farr; Sascha Dublin Journal: Ann Fam Med Date: 2019-07 Impact factor: 5.166
Authors: Jeffrey F Scherrer; Joanne Salas; Kathleen M Chard; Peter Tuerk; Carissa van den Berk-Clark; F David Schneider; Beth E Cohen; Patrick J Lustman; Paula P Schnurr; Matthew J Friedman; Sonya B Norman Journal: J Psychosom Res Date: 2019-10-15 Impact factor: 3.006
Authors: Douglas Barthold; Laura E Gibbons; Zachary A Marcum; Shelly L Gray; C Dirk Keene; Thomas J Grabowski; Nadia Postupna; Eric B Larson; Paul K Crane Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Joanne Salas; Sarah Gebauer; Auston Gillis; Carissa van den Berk-Clark; F David Schneider; Paula P Schnurr; Matthew J Friedman; Sonya B Norman; Peter W Tuerk; Beth E Cohen; Patrick J Lustman; Jeffrey F Scherrer Journal: Nicotine Tob Res Date: 2022-02-01 Impact factor: 5.825
Authors: Juraj Secnik; Hong Xu; Emilia Schwertner; Niklas Hammar; Michael Alvarsson; Bengt Winblad; Maria Eriksdotter; Sara Garcia-Ptacek; Dorota Religa Journal: Alzheimers Res Ther Date: 2021-12-02 Impact factor: 6.982
Authors: Timothy L Wiemken; Joanne Salas; John E Morley; Daniel F Hoft; Christine Jacobs; Jeffrey F Scherrer Journal: J Am Geriatr Soc Date: 2021-12-12 Impact factor: 7.538